Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer
Adam G. Sowalsky,Ines Figueiredo,Rosina T. Lis,Ilsa Coleman,Bora Gurel,Denisa Bogdan,Wei Yuan,Joshua W. Russo,John R. Bright,Nichelle C. Whitlock,Shana Y. Trostel,Anson T. Ku,Radhika A. Patel,Lawrence D. True,Jonathan Welti,Juan M. Jimenez-Vacas,Daniel Nava Rodrigues,Ruth Riisnaes,Antje Neeb,Cynthia T. Sprenger,Amanda Swain,Scott Wilkinson,Fatima Karzai,William L. Dahut,Steven P. Balk,Eva Corey,Peter S. Nelson,Michael C. Haffner,Stephen R. Plymate,Johann S. de Bono,Adam Sharp
DOI: https://doi.org/10.1101/2022.03.10.22271799
2022-03-12
Abstract:Abstract Background Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown clinical utility as a predictive biomarker of AR-targeted therapy resistance in castration-resistant prostate cancer (CRPC), but its importance as predictive biomarker in CSPC remains understudied. Methods We explored multiple approaches to quantify AR-V7 mRNA and protein in prostate cancer cell lines and patient-derived xenograft (PDX) models, in both publicly available and independent institutional clinical cohorts, to identify reliable approaches for detecting AR-V7 mRNA and protein, and its association with clinical outcome. Results In publicly available benign prostate, CSPC and CRPC cohorts, AR-V7 mRNA was much less abundant when detected using reads across splice boundaries than when considering isoform-specific exonic reads. The RM7 AR-V7 antibody had increased sensitivity and specificity for AR-V7 protein detection by immunohistochemistry (IHC) in CRPC cohorts and identified AR-V7 protein reactivity very rarely in CSPC cohorts, when compared to the EPR15656 AR-V7 antibody. Using multiple CRPC PDX models, we demonstrated that AR-V7 expression was exquisitely sensitive to hormonal manipulation. In CSPC cohorts, AR-V7 protein quantification by either assay did not associate with time to development of castration-resistance or overall survival, and intense neoadjuvant androgen-deprivation therapy did not lead to significant detectable AR-V7 mRNA or staining following treatment, and neither pre- nor post-treatment AR-V7 levels associated with the volume of residual disease after therapy. Conclusion This study demonstrates that further analytical validation and clinical qualification is required before AR-V7 can be considered for clinical use in CSPC as a predictive biomarker.